Back Hepatitis B

Hepatitis B

Long-term Adefovir (Hepsera) plus Emtricitabine (Emtriva) vs Adefovir Monotherapy for Chronic Hepatitis B

Antiviral therapy with nucleoside/nucleotide analog agents is effective against chronic hepatitis B virus (HBV) infection, but long-term efficacy is limited by the emergence of drug resistant virus. As reported in the May 2008 Journal of Hepatology, researchers from the University of Hong Kong conducted a trial to determine the efficacy of adefovir dipivoxil (Hepsera) plus emtricitabine (Emtriva) combination therapy in patients with chronic hepatitis B. Adefovir is currently approved for this indication; emtricitabine is approved for the treatment of HIV, but is still under investigation for HBV.

Read more:

Adefovir (Hepsera) for Treatment of Patients with Chronic Hepatitis B Resistant to Lamivudine (Epivir)

In a prospective cohort study, 29 participants with lamivudine-resistant HBV were treated with adefovir (Hepsera) alone, while 23 continued lamivudine and added adefovir.

Read more:

CDC Reports Dramatic Declines in New Cases of Hepatitis A, B, and C

Hepatitis B and C have become growing public health concerns in recent years, as people infected decades ago begin to develop complications of chronic liver disease, including cirrhosis and hepatocellular carcinoma. But the rates of new hepatitis A, B, and C infections have decreased dramatically over the past 10-15 years, according to a new surveillance study by the Centers for Disease Control and Prevention (CDC), published in the March 16, 2007 issue of Morbidity and Mortality Weekly Report.

Read more: